Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Glioblastoma | Research

Prognostic value of preoperative hematological markers in patients with glioblastoma multiforme and construction of random survival forest model

Authors: Xiaozong Duan, Bo Yang, Chengbin Zhao, Boran Tie, Lei Cao, Yuyuan Gao

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Objective

In recent years, an increasing number of studies have revealed that patients’ preoperative inflammatory response, coagulation function, and nutritional status are all linked to the occurrence, development, angiogenesis, and metastasis of various malignant tumors. The goal of this study is to determine the relationship between preoperative peripheral blood neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), systemic immune-inflammatory index (SII), platelet to lymphocyte ratio (PLR), and platelet to fibrinogen ratio (FPR). Prognostic nutritional index (PNI) and the prognosis of glioblastoma multiforme (GBM) patients, as well as establish a forest prediction model that includes preoperative hematological markers to predict the individual GBM patient’s 3-year survival status after treatment.

Methods

The clinical and hematological data of 281 GBM patients were analyzed retrospectively; overall survival (OS) was the primary endpoint. X-Tile software was used to determine the best cut-off values for NLR, SII, and PLR, and the survival analysis was carried out by the Kaplan–Meier method as well as univariate and multivariate COX regression. Afterward, we created a random forest model that predicts the individual GBM patient’s 3-year survival status after treatment, and the area under the curve (AUC) is used to validate the model’s effectiveness.

Results

The best cut-off values for NLR, SII, and PLR in GBM patients’ preoperative peripheral blood were 2.12, 537.50, and 93.5 respectively. The Kaplan–Meier method revealed that preoperative GBM patients with high SII, high NLR, and high PLR had shorter overall survival, and the difference was statistically significant. In addition to clinical and pathological factors. Univariate Cox showed NLR (HR = 1.456, 95% CI: 1.286 ~ 1.649, P < 0.001) MLR (HR = 1.272, 95% CI: 1.120 ~ 1.649, P < 0.001), FPR (HR = 1.183,95% CI: 1.049 ~ 1.333, P < 0.001), SII (HR = 0.218,95% CI: 1.645 ~ 2.127, P < 0.001) is related to the prognosis and overall survival of GBM. Multivariate Cox proportional hazard regression showed that SII (HR = 1.641, 95% CI: 1.430 ~ 1.884, P < 0.001) is also related to the overall survival of patients with GBM. In the random forest prognostic model with preoperative hematologic markers, the AUC in the test set and the validation set was 0.907 and 0.900, respectively.

Conclusion

High levels of NLR, MLR, PLR, FPR, and SII before surgery are prognostic risk factors for GBM patients. A high preoperative SII level is an independent risk factor for GBM prognosis. The random forest model that includes preoperative hematological markers has the potential to predict the individual GBM patient’s 3-year survival status after treatment,and assist the clinicians for making a good clinical decision.
Literature
1.
go back to reference Ma R, Taphoorn MJB, Plaha P. Advances in the management of glioblastoma. J Neurol Neurosurg Psychiatry. 2021;92(10):1103–11.CrossRefPubMed Ma R, Taphoorn MJB, Plaha P. Advances in the management of glioblastoma. J Neurol Neurosurg Psychiatry. 2021;92(10):1103–11.CrossRefPubMed
2.
go back to reference Ostrom QT, Patil N, Cioffi G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22(12 Suppl 2):iv1–96.CrossRefPubMedPubMedCentral Ostrom QT, Patil N, Cioffi G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22(12 Suppl 2):iv1–96.CrossRefPubMedPubMedCentral
4.
go back to reference Hung RJ, Ulrich CM, Goode EL, et al. Cross cancer genomic investigation of inflammation pathway for five common cancers: lung, ovary, prostate, breast, and colorectal cancer. J Natl Cancer Inst. 2015;107(11):djv246.CrossRefPubMedPubMedCentral Hung RJ, Ulrich CM, Goode EL, et al. Cross cancer genomic investigation of inflammation pathway for five common cancers: lung, ovary, prostate, breast, and colorectal cancer. J Natl Cancer Inst. 2015;107(11):djv246.CrossRefPubMedPubMedCentral
5.
go back to reference Barahona Ponce C, Scherer D, Brinster R, et al. Gallstones, body mass index, C-reactive protein, and gallbladder cancer: mendelian randomization analysis of Chilean and European genotype data. Hepatology. 2021;73(5):1783–96.CrossRefPubMed Barahona Ponce C, Scherer D, Brinster R, et al. Gallstones, body mass index, C-reactive protein, and gallbladder cancer: mendelian randomization analysis of Chilean and European genotype data. Hepatology. 2021;73(5):1783–96.CrossRefPubMed
6.
go back to reference Sasaki M, Miyoshi N, Fujino S, et al. The Geriatric Nutritional Risk Index predicts postoperative complications and prognosis in elderly patients with colorectal cancer after curative surgery. Sci Rep. 2020;10(1):10744.CrossRefPubMedPubMedCentral Sasaki M, Miyoshi N, Fujino S, et al. The Geriatric Nutritional Risk Index predicts postoperative complications and prognosis in elderly patients with colorectal cancer after curative surgery. Sci Rep. 2020;10(1):10744.CrossRefPubMedPubMedCentral
7.
go back to reference Khan AA, Akritidis G, Pring T, et al. The neutrophil-to-lymphocyte ratio as a marker of lymph node status in patients with rectal cancer. Oncology. 2016;91(2):69–77.CrossRefPubMed Khan AA, Akritidis G, Pring T, et al. The neutrophil-to-lymphocyte ratio as a marker of lymph node status in patients with rectal cancer. Oncology. 2016;91(2):69–77.CrossRefPubMed
8.
go back to reference Hu H, Yao X, Xie X, et al. Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients. World J Urol. 2017;35(2):261–70.CrossRefPubMed Hu H, Yao X, Xie X, et al. Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients. World J Urol. 2017;35(2):261–70.CrossRefPubMed
9.
go back to reference Gu L, Li H, Chen L, et al. Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget. 2016;7:31926–42.CrossRefPubMedPubMedCentral Gu L, Li H, Chen L, et al. Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget. 2016;7:31926–42.CrossRefPubMedPubMedCentral
10.
go back to reference Chen XY, Pan DL, Xu JH, et al. Serum inflammatory biomarkers contribute to the prognosis prediction in high-grade glioma. Front Oncol. 2021;11:754920.CrossRefPubMed Chen XY, Pan DL, Xu JH, et al. Serum inflammatory biomarkers contribute to the prognosis prediction in high-grade glioma. Front Oncol. 2021;11:754920.CrossRefPubMed
11.
go back to reference Yan P, Li JW, Mo LG, et al. A nomogram combining inflammatory markers and clinical factors predicts survival in patients with diffuse glioma. Medicine. 2021;100(47):e27972.CrossRefPubMedPubMedCentral Yan P, Li JW, Mo LG, et al. A nomogram combining inflammatory markers and clinical factors predicts survival in patients with diffuse glioma. Medicine. 2021;100(47):e27972.CrossRefPubMedPubMedCentral
12.
go back to reference Lopes M, Carvalho B, Vaz R, et al. Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme. J Neurooncol. 2018;136(1):173–80.CrossRefPubMed Lopes M, Carvalho B, Vaz R, et al. Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme. J Neurooncol. 2018;136(1):173–80.CrossRefPubMed
13.
go back to reference Ostrom QT, Cote DJ, Ascha M, et al. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014[J]. JAMA Oncol. 2018;4(9):1254–62.CrossRefPubMedPubMedCentral Ostrom QT, Cote DJ, Ascha M, et al. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014[J]. JAMA Oncol. 2018;4(9):1254–62.CrossRefPubMedPubMedCentral
14.
go back to reference Iwamoto FM, Reiner AS, Panageas KS, et al. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64(6):628–34.CrossRefPubMed Iwamoto FM, Reiner AS, Panageas KS, et al. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64(6):628–34.CrossRefPubMed
15.
16.
go back to reference Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006;24(16):2563–9.CrossRefPubMed Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006;24(16):2563–9.CrossRefPubMed
17.
go back to reference Zhang Y, Sun Y, Zhang Q. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis. Cancer Cell Int. 2020;20:224.CrossRefPubMedPubMedCentral Zhang Y, Sun Y, Zhang Q. Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis. Cancer Cell Int. 2020;20:224.CrossRefPubMedPubMedCentral
18.
go back to reference Wang K, Karin M. Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res. 2015;128:173–96.CrossRefPubMed Wang K, Karin M. Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res. 2015;128:173–96.CrossRefPubMed
19.
go back to reference Wang TT, Zhao YL, Peng LS, et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut. 2017;66(11):1900–11.CrossRefPubMed Wang TT, Zhao YL, Peng LS, et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut. 2017;66(11):1900–11.CrossRefPubMed
20.
go back to reference Chen SC, Wu PC, Wang CY, et al. Evaluation of cytotoxic T lymphocyte-mediated anticancer response against tumor interstitium-simulating physical barriers. Sci Rep. 2020;10(1):13662.CrossRefPubMedPubMedCentral Chen SC, Wu PC, Wang CY, et al. Evaluation of cytotoxic T lymphocyte-mediated anticancer response against tumor interstitium-simulating physical barriers. Sci Rep. 2020;10(1):13662.CrossRefPubMedPubMedCentral
22.
go back to reference Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2016;19(1):20–7.CrossRefPubMedPubMedCentral Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2016;19(1):20–7.CrossRefPubMedPubMedCentral
23.
go back to reference Dymicka-Piekarska V, Koper-Lenkiewicz OM, Zińczuk J, et al. Inflammatory cell-associated tumors. Not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment. The unique role of tumor associated platelets (TAPs). Cancer Immunol Immunother. 2021;70(6):1497–510.CrossRefPubMed Dymicka-Piekarska V, Koper-Lenkiewicz OM, Zińczuk J, et al. Inflammatory cell-associated tumors. Not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment. The unique role of tumor associated platelets (TAPs). Cancer Immunol Immunother. 2021;70(6):1497–510.CrossRefPubMed
24.
go back to reference Lolli C, Umberto B, Lisa D, et al. Systemic immune—inflammation index predicts the clinical outcome in patients with mCRPC treated with Abirateronc. Front Pharmacol. 2016;7:376.CrossRefPubMedPubMedCentral Lolli C, Umberto B, Lisa D, et al. Systemic immune—inflammation index predicts the clinical outcome in patients with mCRPC treated with Abirateronc. Front Pharmacol. 2016;7:376.CrossRefPubMedPubMedCentral
25.
go back to reference Cho A, McKelvey KJ, Lee A, et al. The intertwined fates of inflammation and coagulation in glioma. Mamm Genome. 2018;29(11–12):806–16.CrossRefPubMed Cho A, McKelvey KJ, Lee A, et al. The intertwined fates of inflammation and coagulation in glioma. Mamm Genome. 2018;29(11–12):806–16.CrossRefPubMed
26.
go back to reference Aminianfar A, Vahid F, Shayanfar M, et al. The association between the dietary inflammatory index and glioma: a case-control study. Clin Nutr. 2020;39(2):433–9.CrossRefPubMed Aminianfar A, Vahid F, Shayanfar M, et al. The association between the dietary inflammatory index and glioma: a case-control study. Clin Nutr. 2020;39(2):433–9.CrossRefPubMed
27.
go back to reference Rathore S, Akbari H, Doshi J, et al. Radiomic signature of infiltration in peritumoral edema predicts subsequent recurrence in glioblastoma: implications for personalized radiotherapy planning. J Med Imaging. 2018;5(2):021219.CrossRef Rathore S, Akbari H, Doshi J, et al. Radiomic signature of infiltration in peritumoral edema predicts subsequent recurrence in glioblastoma: implications for personalized radiotherapy planning. J Med Imaging. 2018;5(2):021219.CrossRef
28.
go back to reference Zihao W, Gao Lu, Xiaopeng G, et al. Development and validation of a nomogram with an autophagy-related gene signature for predicting survival in patients with glioblastoma. Aging. 2019;11(24):12246–69.CrossRef Zihao W, Gao Lu, Xiaopeng G, et al. Development and validation of a nomogram with an autophagy-related gene signature for predicting survival in patients with glioblastoma. Aging. 2019;11(24):12246–69.CrossRef
29.
go back to reference Gorlia Th, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981–22981/CE.3. Lancet Oncol. 2008;9(1):29–38.CrossRefPubMed Gorlia Th, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981–22981/CE.3. Lancet Oncol. 2008;9(1):29–38.CrossRefPubMed
30.
go back to reference Liang R, Zhi Y, Zheng G, et al. Analysis of long non-coding RNAs in glioblastoma for prognosis prediction using weighted gene co-expression network analysis, Cox regression, and L1-LASSO penalization. OncoTargets Ther. 2019;12:157–68.CrossRef Liang R, Zhi Y, Zheng G, et al. Analysis of long non-coding RNAs in glioblastoma for prognosis prediction using weighted gene co-expression network analysis, Cox regression, and L1-LASSO penalization. OncoTargets Ther. 2019;12:157–68.CrossRef
31.
go back to reference Zhigang P, Chen Yu, Hui C, et al. Protein disulfide isomerases are promising targets for predicting the survival and tumor progression in glioma patients. Aging. 2020;12(3):2347–72.CrossRef Zhigang P, Chen Yu, Hui C, et al. Protein disulfide isomerases are promising targets for predicting the survival and tumor progression in glioma patients. Aging. 2020;12(3):2347–72.CrossRef
Metadata
Title
Prognostic value of preoperative hematological markers in patients with glioblastoma multiforme and construction of random survival forest model
Authors
Xiaozong Duan
Bo Yang
Chengbin Zhao
Boran Tie
Lei Cao
Yuyuan Gao
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10889-0

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine